Synthesis of chiral 1-benzyl-1,2,3,4-tetra-hydroisoquinolines by
asymmetric reduction
    21.
    发明授权
    Synthesis of chiral 1-benzyl-1,2,3,4-tetra-hydroisoquinolines by asymmetric reduction 失效
    通过不对称还原合成手性1-苄基-1,2,3,4-四氢异喹啉

    公开(公告)号:US4727146A

    公开(公告)日:1988-02-23

    申请号:US748854

    申请日:1985-06-26

    申请人: Kenner C. Rice

    发明人: Kenner C. Rice

    摘要: In a short total synthesis of morphinan compounds, derivatives of 1-benzyl-1,2,3,4-tetrahydroisoquinoline are produced. Certain of these compounds, although highly aromatic and functionalized, can be optically resolved. The optically active enantiomers can serve as important intermediates for both natural and unnatural opioids. As a special function of this invention, certain of the derivatives, namely 4'-6' and 7'-9', may be hydrogenated to 1'-3' derivative by asymmetric reduction either of the catalytic or chemical type.

    摘要翻译: 在短的全合成吗啡喃化合物中,制备1-苄基-1,2,3,4-四氢异喹啉的衍生物。 这些化合物中的某些虽然高度芳族和官能化,但可以光学拆分。 光学活性对映体可用作天然和非天然阿片样物质的重要中间体。 作为本发明的特殊功能,某些衍生物即4'-6'和7'-9'可以通过催化或化学类型的不对称还原被氢化成1'-3'衍生物。

    Practical total synthesis unnatural enantiomers of opium-derived
morphinans
    22.
    发明授权
    Practical total synthesis unnatural enantiomers of opium-derived morphinans 失效
    鸦片衍生的吗啡烷的实际全合成非天然对映异构体

    公开(公告)号:US4521601A

    公开(公告)日:1985-06-04

    申请号:US477970

    申请日:1983-03-23

    申请人: Kenner C. Rice

    发明人: Kenner C. Rice

    CPC分类号: C07D217/20

    摘要: This invention relates to compounds which may be described as the unnatural enantiomers of morphine agonists and antagonists, which are useful as antitussives. The synthesis utilized is capable of producing all of the unnatural enantiomers of medically important opium derivatives of the morphinan type, including thebaine.

    摘要翻译: 本发明涉及可被描述为可用作镇咳药的吗啡激动剂和拮抗剂的非天然对映异构体的化合物。 所用的合成物能够产生所有的吗啡喃类药物重要的鸦片衍生物的非天然对映异构体,包括蒂巴因。

    Methods of o-demethylation and n-deprotection
    23.
    发明授权
    Methods of o-demethylation and n-deprotection 失效
    去甲基化和去脱保护的方法

    公开(公告)号:US06291675B1

    公开(公告)日:2001-09-18

    申请号:US09194510

    申请日:1999-07-06

    IPC分类号: C07D48902

    摘要: The present invention provides a method for N-deprotecting an opioid compound, a method for N-deprotecting and O-demethylating an opioid compound, a method for O-demethylating an opioid compound, and a method for O-demethylating a nonpeptidic delta agonist compound or an opioid compound having a tertiary amide with no significant reaction at amide groups.

    摘要翻译: 本发明提供了对阿片样物质进行N-去保护的方法,对于阿片样物质进行N-脱保护和O-脱甲基化的方法,对阿片样物质进行O-去甲基化的方法,以及将非肽δ激动剂化合物O-脱甲基化的方法 或具有在酰胺基上没有显着反应的叔酰胺的阿片样物质化合物。

    Nitrogen-containing cyclohetero cycloalkylaminoaryl derivatives for CNS
disorders
    24.
    发明授权
    Nitrogen-containing cyclohetero cycloalkylaminoaryl derivatives for CNS disorders 失效
    用于CNS疾病的含氮环杂环烷基氨基芳基衍生物

    公开(公告)号:US5739158A

    公开(公告)日:1998-04-14

    申请号:US877190

    申请日:1992-07-01

    CPC分类号: C07D295/135

    摘要: Certain nitrogen-containing cyclohetero cycloalkylaminoaryl compounds are described for treatment of CNS disorders such as cerebral ischemia, psychotic disorders, convulsions and parkinsonism. Compounds of particular interest are of the formula ##STR1## wherein R.sup.1 is selected from hydrido, loweralkyl, cycloalkylalkyl of four to six carbon atoms and loweralkenylloweralkyl; wherein each of R.sup.2 and R.sup.3 is independently selected from hydrido and loweralkyl; wherein each of R.sup.4 through R.sup.7, R.sup.10 and R.sup.11 is independently selected from hydrido, hydroxy, loweralkyl, benzyl, phenoxy, benzyloxy and haloloweralkyl; wherein n is a number selected from four through six; wherein p is a number selected from zero through four; wherein q is a number selected from three through five; wherein A is selected from phenyl, naphthyl and thienyl; wherein any of the foregoing A groups can be further substituted with one or more substituents independently selected from hydrido, hydroxy, loweralkyl, loweralkoxy, halo, haloloweralkyl, amino, monoloweralkylamino and diloweralkylamino; or a pharmaceutically acceptable salt thereof.

    摘要翻译: PCT No.PCT / US91 / 00688 Sec。 371日期:1992年7月1日 102(e)日期1992年7月1日PCT 1991年1月31日PCT PCT。 WO91 / 12247 PCT出版物 日期1991年8月22日描述了含氮环杂环烷基氨基芳基化合物用于治疗中枢神经系统疾病如脑缺血,精神障碍,抽搐和帕金森综合征。 特别感兴趣的化合物具有式为四氟化烷基,四至六个碳原子的环烷基烷基和低级链烯基低级烷基; 其中R2和R3各自独立地选自氢和低级烷基; 其中R 4至R 7,R 10和R 11各自独立地选自氢,羟基,低级烷基,苄基,苯氧基,苄氧基和卤代低级烷基; 其中n是选自四至六的数字; 其中p是选自零至四的数字; 其中q是选自三至五的数; 其中A选自苯基,萘基和噻吩基; 其中前述A基团中的任一个可以进一步被一个或多个独立地选自氢,羟基,低级烷基,低级烷氧基,卤素,卤代低级烷基,氨基,单低级烷基氨基和二低级烷基氨基的取代基取代。 或其药学上可接受的盐。

    N-(1-thienylcycloalkyl)alkenylamines for treatment of neurotoxic injury
    25.
    发明授权
    N-(1-thienylcycloalkyl)alkenylamines for treatment of neurotoxic injury 失效
    用于治疗神经毒性损伤的N-(1-噻吩基环烷基)烯基胺

    公开(公告)号:US5604255A

    公开(公告)日:1997-02-18

    申请号:US344433

    申请日:1994-11-23

    CPC分类号: C07D409/06 C07D333/20

    摘要: Compounds, compositions and methods of treatment are described to control brain damage associated with anoxia or ischemia which typically follows stroke, cardiac arrest or perinatal asphyxia. The treatment includes administration of an N-(1-thienylcycloalkyl)alkenylamine compound as an antagonist to inhibit excitotoxic actions at major neuronal excitatory amino acid receptor sites. Compounds of most interest are those of the formula ##STR1## wherein R.sup.1 is one or more groups selected from hydrido, alkyl of one to about five carbon atoms, cycloalkyl of three to about five carbon atoms, alkenyl of two to about five carbon atoms, hydroxyl and alkoxy; wherein each of R.sup.2 is one or more groups selected from hydrido, alkyl of one to about five carbon atoms, cycloalkyl of three to about five carbon atoms, alkenyl of two to about five carbon atoms, hydroxyl, oxo and alkoxy; wherein R.sup.5 is one or more groups selected from hydrido, alkyl of one to about five carbon atoms, cycloalkyl of three to about five carbon atoms, alkenyl of two to about five carbon atoms, hydroxyl and alkoxy; and wherein the broken line within the N-containing ring represents a double bond between any two adjacent carbon atoms

    摘要翻译: 描述了治疗的化合物,组合物和方法以控制与缺氧或缺血相关的脑损伤,其通常在中风,心脏骤停或围产期窒息之后。 治疗包括施用N-(1-噻吩基环烷基)链烯基胺化合物作为拮抗剂,以抑制主要神经元兴奋性氨基酸受体位点的兴奋性毒性作用。 最感兴趣的化合物是下式的化合物,其中R 1是一个或多个选自氢,烷基一至约五个碳原子,三至五个碳原子的环烷基,二至五个碳原子的烯基, 羟基和烷氧基; 其中R2各自为选自氢化物,1至约5个碳原子的烷基,3至约5个碳原子的环烷基,2至约5个碳原子的链烯基,羟基,氧代和烷氧基; 其中R5是一个或多个选自氢化的,一至五个碳原子的烷基,三个至五个碳原子的环烷基,二个至五个碳原子的烯基,羟基和烷氧基的基团; 并且其中所述含N环内的虚线表示任意两个相邻碳原子之间的双键

    Preparation of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines by
optical resolution
    28.
    发明授权
    Preparation of chiral 1-benzyl-1,2,3,4-tetrahydroisoquinolines by optical resolution 失效
    通过光学拆分制备手性1-苄基-1,2,3,4-四氢异喹啉

    公开(公告)号:US4410700A

    公开(公告)日:1983-10-18

    申请号:US265469

    申请日:1981-05-20

    申请人: Kenner C. Rice

    发明人: Kenner C. Rice

    摘要: In a short total synthesis of morphinan compounds, derivatives of 1-benzyl-1,2,3,4-tetrahydroisoquinoline are produced. Certain of these compounds, although highly aromatic and functionalized, can be optically resolved. The optically active enantiomers can serve as important intermediates for both natural and unnatural opioids.

    摘要翻译: 在短的全合成吗啡喃化合物中,制备1-苄基-1,2,3,4-四氢异喹啉的衍生物。 这些化合物中的某些虽然高度芳族和官能化,但可以光学拆分。 光学活性对映体可用作天然和非天然阿片样物质的重要中间体。